Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT

Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy right now. Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on September 10, retaining the price target of $1,190.00.

The analyst supported the optimistic outlook with the promising outlook for the company’s obesity treatment, tirzepatide, stating that the treatment attained the highest cost-effectiveness rating in the recent draft report by ICER.

According to the analyst, this highlights tirzepatide’s superior efficacy in weight loss compared to lifestyle modifications alone, and the positive evaluation is anticipated to boost payer coverage and streamline access to the drug as the value of weight loss and cardiovascular benefits gains increased recognition.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.